INS and type 2 diabetes mellitus: Glimepiride (GLM) Fig. 1b, 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl] phenyl] sulfonyl]-3-(trans-4-methylcyclohexyl) urea [4], is a third-generation sulfonylurea with hypoglycemic activity, it increases the secretion of insulin by activating beta cells and is used for the management of T2DM to improve blood glucose control [6].